University of Patras
Προοπτική μελέτη θεραπείας της επιπολής φλεβικής θρόμβωσης κάτω άκρων με τινζαπαρίνη
Abstract
dc:descriptionPURPOSE: To identify risk factors for recurrent thromboembolic events (RTEs) and define the optimum duration of treatment with tinzaparin in patients with superficial vein thrombosis (SVT) of the lower limbs.MATERIAL AND METHODS: A total of 147 consecutive patients with significant SVT, treated with subcutaneously administered tinzaparin. The composite primary endpoint of the study was RTE, deep-vein thrombosis (DVT) and/or pulmonary embolism (PE) at 120 days. Patients were stratified into group A, where patients received a variable dose of tinzaparin for up to 60 days (n=98), and a subsequent group B-ext, where patients received a standardized intermediate dose of tinzaparin (n=49) for 90 days. RESULTS: RTEs occurred in 15/147 patients (10.2%), including recurrent SVT (n=10), DVT (n=4) and fatal PE (n=1). RTEs were less frequent in group B-ext (0% versus 15.3% for group A, p=0.004), a difference that remained significant at the one-year follow-up. Clinically extensive SVT was an independent predictor for RTEs (HR 5.94, 95% CI 2.05-17.23, p=0.001, Cox regression). Predictors or DVT or PE in group A included clinically extensive SVT (p=0.004), absence of local pain (p=0.023) and the ultrasound findings of superficial axial vein thrombosis (any, p=0.006 or isolated, p=0.036) and multiple thrombosed superficial venous sites (p<0.001). CONCLUSIONS: An extended three-month regimen of tinzaparin in patients with SVT of the lower limbs is more effective than a shorter course and may be desirable in patients with risk factors.
Degree
thesis:*- Grantor dc:publisher
- University of Patras
- Year dc:date
- 2018
Author and committee
dc:creator, dc:contributor.*- Authors dc:creator
-
- Nikolakopoulos, Konstantinos
- Νικολακόπουλος, Κωνσταντίνος
Subjects
dc:subject × 6Rights
- Language dc:language
- gre
Identifiers
dc:identifier.*- Identifier
- 10.12681/eadd/44494